anaprazole + amoxicillin + clarithromycin

Anaprazole + amoxicillin + clarithromycin is a combination therapy, intended for the eradication of *Helicobacter pylori* (H. pylori) infection in the gastrointestinal tract, most commonly associated with peptic ulcer disease. This regimen combines three agents with complementary mechanisms: - **Anaprazole** is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the gastric H+/K+ ATPase in parietal cells, thereby creating a less acidic environment conducive to bacterial eradication and increasing the efficacy of accompanying antibiotics. - **Amoxicillin** is a penicillin-class beta-lactam antibiotic that inhibits bacterial cell wall synthesis, leading to cell lysis and death, particularly effective against *H. pylori* at higher gastric pH levels. - **Clarithromycin** is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, thereby halting bacterial growth and replication. The combination is primarily indicated for the treatment and eradication of *H. pylori*, reducing the risk of ulcer recurrence. Anaprazole itself is a newer proton pump inhibitor structurally related to other PPIs; specific combination products with anaprazole are investigational or regionally available, modeled after established triple therapies such as omeprazole + amoxicillin + clarithromycin or lansoprazole + amoxicillin + clarithromycin[1][2][3][4][5][6][7].